Literatur
-
1
Baccarani M, Saglio G, Goldman J. et al .
Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood.
2006;
[Epub ahead of print]
-
2
Branford S, Rudzki Z, Parkinson I. et al .
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Blood.
2004;
104
2926-2932
-
3
Branford S, Rudzki Z, Walsh S. et al .
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood.
2003;
102
276-283
-
4
Deininger M, Buchdunger E, Druker B J.
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood.
2005;
105
2640-2653
-
5
Druker B J, Guilhot F, O’Brien S. et al .
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study.
J Clin Oncol.
2006;
(Suppl 18S)
24
6506
-
6
Druker B J, Tamura S, Buchdunger E. et al .
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nature Med.
1996;
2
561-566
-
7
Hochhaus A, Lin F, Reiter A. et al .
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon alpha.
Br J Haematol.
1995;
91
126-131
-
8
Hughes T P, Deininger M W, Hochhaus A. et al .
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood.
2006;
108
28-37
-
9
Hughes T P, Kaeda J, Branford S. et al .
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
N Engl J Med.
2003;
349
1423-1432
-
10
Kantarjian H, Giles F, Wunderle L. et al .
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
N Engl J Med.
2006;
354
2542-2551
-
11
Kantarjian H, Sawyers C, Hochhaus A. et al .
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med.
2002;
346
645-652
-
12
Lange T, Bumm T, Mueller M. et al .
Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Leukemia.
2005;
19
1262-1265
-
13
O’Brien S G, Guilhot F, Larson R A. et al .
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med.
2003;
348
994-1004
-
14
O’Hare T, Walters D K, Stoffregen E P. et al .
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Clin Cancer Res.
2005;
11
6987-6993
-
15
Olavarria E, Kanfer E, Szydlo R. et al .
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood.
2001;
97
1560-1565
-
16
Simonsson B. on behalf of the IRIS (International Randomized IFN vs STI571) Study Group .
Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): Update from the IRIS study.
Blood.
2005;
106
, abstract #166
-
17
Soverini S, Martinelli G, Rosti G. et al .
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
J Clin Oncol.
2005;
23
4100-4109
-
18
Talpaz M, Shah N P, Kantarjian H. et al .
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med.
2006;
354
2531-2541
-
19
Willis S G, Lange T, Demehri S. et al .
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Blood.
2005;
106
2128-2137
Dr. med. Thoralf Lange
Abteilung Hämatologie/Onkologie, Medizinische Klinik II, Universitätsklinikum Leipzig
Johannisallee 32A
04103 Leipzig
Phone: 0341/9713050
Fax: 0341/9713059
Email: langet@medizin.uni-leipzig.de
